You are here

Article Text

Article menu
Download PDFPDF
Letter
Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus
  1. H-M Lorenz1,
  2. M Grunke2,
  3. J Wendler2,
  4. P A Heinzel3,
  5. J R Kalden2
  1. 1Division of Rheumatology, Department of Medicine V, University of Heidelberg, Heidelberg, Germany
  2. 2Department of Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
  3. 3Euro Nippon Kayaku, Frankfurt, Germany
  1. Correspondence to:
    Professor H-M Lorenz
    Division of Rheumatology, Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; Hannes_Lorenzmed.uni-heidelberg.de

https://doi.org/10.1136/ard.2005.035329

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Optimal treatment for patients with relapsing lupus nephritis remains unclear. The ability of 15-deoxyspergualin (gusperimus; 15-DSG) to suppress systemic lupus erythematosus (SLE)-like diseases has been demonstrated in animals and humans.1–4 15-DSG exerted no nephrotoxicity or hepatotoxicity but reversibly induced leucocytopenia.5,6

    In this study we aimed at evaluating the safety of 15-DSG in the treatment of glomerulonephritis associated with SLE.

    CASE REPORTS

    Table 1 shows the patient characteristics.

    View this table:
    • In this window
    • In a new window
    Table 1

     Details of the patients’ history, especially previous immunosuppressive treatment, signs of SLE-GN activity or general SLE activity at entry, and indicators for response during/after 15-DSG treatment

    15-DSG was provided by Nippon Kayaku Co Ltd, Tokyo, Japan. Patients gave their informed consent, and 15-DSG 0.5 mg/kg normal body weight (height in cm minus 100)/day was self administered subcutaneously for 14 days, followed by a break of 7 days ( = 1 cycle). The dose was adjusted (dependent on efficacy or safety, or both) after cycles 4 and 6 to 0.35 mg/kg and 0.25 mg/kg, or 0.7 mg/kg and 1.0 mg/kg.

    Patient 1

    After a bolus, daily …

    View Full Text